WAVE Life Sciences Ltd. $WVE Shares Purchased by Schroder Investment Management Group

Schroder Investment Management Group boosted its stake in WAVE Life Sciences Ltd. (NASDAQ:WVE) by 29.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 621,378 shares of the company’s stock after buying an additional 142,109 shares during the quarter. Schroder Investment Management Group owned approximately 0.39% of WAVE Life Sciences worth $4,039,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Ameritas Investment Partners Inc. lifted its position in shares of WAVE Life Sciences by 18.7% in the second quarter. Ameritas Investment Partners Inc. now owns 11,444 shares of the company’s stock valued at $74,000 after acquiring an additional 1,802 shares in the last quarter. Prudential Financial Inc. acquired a new position in WAVE Life Sciences in the 2nd quarter valued at $80,000. Knott David M Jr purchased a new position in WAVE Life Sciences in the 1st quarter valued at $81,000. Ascent Group LLC acquired a new stake in WAVE Life Sciences during the 1st quarter worth $83,000. Finally, Virtus Investment Advisers LLC boosted its position in WAVE Life Sciences by 10.2% during the second quarter. Virtus Investment Advisers LLC now owns 13,060 shares of the company’s stock worth $85,000 after acquiring an additional 1,210 shares during the last quarter. 89.73% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on WVE. Leerink Partners set a $26.00 target price on shares of WAVE Life Sciences in a research note on Wednesday, September 3rd. Wells Fargo & Company cut their price target on WAVE Life Sciences from $18.00 to $16.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $12.00 price target on shares of WAVE Life Sciences in a research report on Monday, October 27th. B. Riley reissued a “buy” rating on shares of WAVE Life Sciences in a research report on Thursday, September 4th. Finally, Wedbush raised their target price on shares of WAVE Life Sciences from $18.00 to $20.00 and gave the company an “outperform” rating in a report on Tuesday, November 11th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.50.

Insider Buying and Selling

In related news, Director Adrian Rawcliffe sold 16,115 shares of WAVE Life Sciences stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $6.79, for a total transaction of $109,420.85. Following the sale, the director directly owned 12,700 shares in the company, valued at $86,233. This trade represents a 55.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 23.98% of the stock is owned by corporate insiders.

WAVE Life Sciences Stock Down 1.7%

Shares of WVE opened at $7.49 on Friday. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of -9.99 and a beta of -1.72. WAVE Life Sciences Ltd. has a 52-week low of $5.28 and a 52-week high of $15.72. The stock has a 50 day moving average price of $7.50 and a 200 day moving average price of $7.59.

WAVE Life Sciences (NASDAQ:WVE) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). The company had revenue of $7.61 million for the quarter, compared to analyst estimates of $9.85 million. WAVE Life Sciences had a negative return on equity of 75.61% and a negative net margin of 111.64%. On average, equities analysts anticipate that WAVE Life Sciences Ltd. will post -1.14 EPS for the current fiscal year.

About WAVE Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.